

#2 Attachment 1

PTO/SB/08 (2-92)

Sheet 1 of 3

Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>	Docket Number 273012011100	Application Number 09/556,833
	Applicant Patrick Mark CURRY, et al.	
	Filing Date: April 21, 2000	Group Art Unit 1614
	Mailing Date March 20, 2001	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
mm	1.	12/1992	5,171,749	Levy et al.	514	410	
	2.	06/1999	5,929,105	Sternberg et al	514	410	
	3.	03/1984	4,436,727	Ribi	424	177	
	4.	09/1989	4,866,034	Ribi	514	2	
	5.	03/1990	4,912,094	Myers et al.	514	54	
	6.	04/1990	4,920,143	Levy et al.	514	410	
	7.	11/1989	4,883,790	Levy et al.	540	145	
	8.	03/1992	5,095,030	Levy et al.	514	410	
	9.	03/1999	5,880,145	Sternberg et al.	514	410	
	10.	05/1994	5,308,608	Dolphin et al.	424	9	
	11.	04/1995	5,405,957	Tang et al.	540	472	
	12.	04/1996	5,512,675	Tang et al.	540	472	
	13.	03/1998	5,726,304	Tang et al.	540	145	
	14.	12/1992	5,171,741	Dougherty	514	185	
	15.	11/1998	5,831,088	Dolphin et al.	540	474	
	16.	12/1997	5,703,230	Boyle et al.	540	145	
	17.	03/1999	5,883,246	Bruckner et al.	540	145	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
-------------------	----------	------	--------------	---------	-------	----------	-----------------------

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
mm	18.	Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD (1996) Hematologic effects of flt3 ligand <i>in vivo</i> in mice. <i>Blood</i> 88:2004-2012

EXAMINER:

Maurice

DATE CONSIDERED:

8-81-01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 273012011100

Application Number 09/556,833

Applicant

Patrick Mark CURRY, et al.


Filing Date: April 21, 2000

Group Art Unit 1614

Mailing Date March 20, 2001

- mm
19. Burger, U.L., Chang, M.P., Nagoshi, M., Goedegebuure, P.S. and Eberlein, T.J. (1996) Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro. *Annals of Surgical Oncology*, 3:580-587.
 20. Chen, W.R., Adams, R.L., Carubelli, R. and Nordquist, R.E. (1997) Laser-photosensitizer assisted immunotherapy: a novel modality for cancer treatment. *Cancer Letters*, 115:25-30.
 21. Cho, Y.H., Straight, R.C. and Smith, J.A., Jr. (1992) Effects of photodynamic therapy in combination with intravesical drugs in a murine bladder tumor model. *J Urol*, 147:743-6.
 22. Cox, J.C. and Coulter, A.R. (1997) Adjuvants--a classification and review of their modes of action. *Vaccine*, 15:248-56.
 23. Dougherty, T.J., Grindley, G.B., Fiel, R., Weishaupt, K.R. and Boyle, D.G. (1975) Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. *Journal of the National Cancer Institute*, 55:115-119.
 24. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. *Cancer Res* 58:380-383.
 25. Evans, S., Matthews, W., Perry, R., Fraker, D., Norton, J. and Pass, H.I. (1990) Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. *Journal of the National Cancer Institute*, 82:34-39.
 26. Fingar, V.H., Wieman, T.J. and Doak, K.W. (1990) Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. *Cancer Research*, 50:2599-2603.
 27. Gore, M. and Riches, P. (1996) The history of immunotherapy. In Gore, M. and Riches, P. (eds.), *Immunotherapy in cancer*. John Wiley & Sons, Chichester, pp. 1-9.
 28. Granville, D.J., Levy, J.G. and Hunt, D.W. (1998) Photodynamic treatment with benzoporphyrin derivative monoacid ring A produces protein tyrosine phosphorylation events and DNA fragmentation in murine P815 cells. *Photochem Photobiol*, 67:358-62.
 29. Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD (1995) The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells *in vitro*: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors. *J Exp Med* 181:1357-1363.
 30. Korbelik, M., Kros, G. and Chaplin, D.J. (1993) Can PDT be potentiated by immunotherapy. *Proc. SPIE*, 1616:192-198.
 31. Korbelik M: Induction of tumor immunity by photodynamic therapy. *J Clin Laser Med Surg* (1996) 14:329-334.
 32. Korbelik, M., Naraparaju, V.R. and Yamamoto, N. (1997) Macrophage-directed immunotherapy as

EXAMINER:



DATE CONSIDERED:

3-31-01

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 273012011100

Application Number 09/556,833

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Patrick Mark CURRY, et al.

Filing Date: April 21, 2000

Group Art Unit 1614

Mailing Date March 20, 2001

- mt*
33. adjuvant to photodynamic therapy of cancer. *British Journal of Cancer*, 75:202-7.
34. Korbely, M. and Cecic, I. (1998) Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment. *J Photochem Photobiol B*, 44:151-8.
35. Krosi, G. and Korbely, M. (1994) Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). *Cancer Letters*, 84:43-49.
36. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. *J Exp Med* 184:1953-1962.
37. Myers, R.C., Lau, B.H., Kunihiro, D.Y., Torrey, R.R., Woolley, J.L. and Tosk, J. (1989) Modulation of hematoporphyrin derivative-sensitized phototherapy with corynebacterium parvum in murine transitional cell carcinoma. *Urology*, 33:230-235.
38. Nseyo, U.O., Whalen, R.K., Duncan, M.R., Berman, B. and Lundahl, S. (1989) Immune response following photodynamic therapy for bladder cancer. *Proceedings of the Society of Photo-Optical Instrumentation Engineers*, 1065:66-72.
39. Section 3: Treatment of metastatic cancer to bone. In DeVita Jr., V.T., Hellman, S. and Rosenberg, S.A. (eds.), *Cancer: Principles and Practice*. J.B. Lippincott Company, Philadelphia, Vol. 2, pp. 2298-2317.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.